Research Horizons
In NEJM: Dose Escalation Best Approach for Sickle Cell Med in Africa
Post Date: June 25, 2020 | Publish Date: June 25, 2020
Russell Ware, MD, PhD
“The study shows clearly that the optimized dosing strategy for hydroxyurea, though it requires more effort than a fixed-dose treatment regimen, results in far better outcomes for children with sickle cell anemia,”
— Russell Ware, MD, PhD
Publication Information
| Original Title: | Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa |
|---|---|
| Published in: | New England Journal of Medicine |
| Publish date: | June 25, 2020 |
Research Areas
- > Asthma and Allergy
- > Autoimmune Disorders
- > Big Data and Analytics
- > Cancer
- > Community Health
- > Diabetes and Obesity
- > Digestive System
- > Emergency and Critical Care
- > Genomics and Development
- > Health Inequities
- > Heart and Lung
- > Imaging Sciences
- > Infectious Diseases and Vaccines
- > Mind Brain Behavior
- > Organoids
- > Ortho, Sports Med and Rehab
- > Perinatal
- > Quality and Safety
- > Rare Diseases
- > Surgical Science
- > Tools for Science
Latest Posts
About this blog
The Research Horizons blog features news and insights about the latest discoveries and innovations developed by the scientists of Cincinnati Children's. This blog does not provide medical advice, diagnosis, or treatment.